GlassScriptPhysician profile
Daniel Zuckerbrod
NPI 1033104773
$16,093.46
in general payments reported to CMS, 2019-2025
36 companies · $2,276 in 2025
The $2,276 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,038 · 2020: $1,187 · 2021: $3,372 · 2022: $3,894 · 2023: $2,187 · 2024: $2,139 · 2025: $2,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,602.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $4,165.25 | 2021-2024 | Iluvien, Yutiq |
| Alcon Vision LLC | $1,540.06 | 2019-2025 | Rocklatan, Rhopressa, Hydrus Microstent |
| Allergan, INC. | $1,313.44 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $1,215.80 | 2019-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $934.45 | 2022-2025 | Durysta, Lumigan, Ozurdex |
| Bausch & Lomb Americas INC. | $912.06 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Aerie Pharmaceuticals, INC. | $800.63 | 2019-2021 | |
| Amgen INC. | $668.35 | 2024-2025 | Tepezza |
| Sight Sciences, INC. | $582.56 | 2022-2025 | Omni Surgical System, Tearcare System, Sion Surgical Instrument |
| Novartis Pharmaceuticals Corporation | $531.66 | 2019-2023 | |
| Oyster Point Pharma, INC. | $352.32 | 2022-2025 | Tyrvaya, Ryzumvi |
| Apellis Pharmaceuticals, INC. | $312.86 | 2022-2025 | Syfovre |
| Eyevance Pharmaceuticals LLC | $296.86 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $292.73 | 2024-2025 | Xdemvy |
| Rxsight INC | $278.90 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $262.57 | 2022-2025 | Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
| Kala Pharmaceuticals, INC. | $249.99 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $231.80 | 2022-2025 | Cequa |
| Mallinckrodt Hospital Products INC. | $169.52 | 2024-2025 | Acthar |
| Shire North American Group INC | $149.46 | 2019 | |
| Harrow Eye, LLC | $137.57 | 2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $108.34 | 2019-2020 | |
| New World Medical,INC. | $84.80 | 2019-2024 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Genentech USA, INC. | $80.35 | 2022-2024 | Vabysmo |
| Ivantis, INC | $76.36 | 2021 | |
| Biotissue Holdings INC. | $74.77 | 2024 | |
| Maculogix, INC. | $54.96 | 2020 | |
| Lkc Technologies, INC. | $35.99 | 2024 | |
| Dompe US, INC. | $31.16 | 2024-2025 | Oxervate |
| Rayner Intraocular Lenses Limited | $30.10 | 2022-2023 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Thea Pharma INC. | $30.02 | 2025 | Iyuzeh |
| Tearlab Corp | $22.28 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Ani Pharmaceuticals, INC. | $17.86 | 2025 | Yutiq |
| Johnson & Johnson Surgical Vision, INC. | $15.07 | 2021 | |
| Eyepoint US, INC. | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Zuckerbrod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.